- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01841528
Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome (FreFro-PCOS)
Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a multi-center, prospective, randomized (1:1 ratio)clinical trial of frozen-thawed embryo transfer vs. fresh embryo transfer after a uniform gonadotropin-releasing hormone (GnRH) antagonist protocol in infertile PCOS patients receiving IVF therapy. Qualified 1180 patients are randomized into either of two groups: group A will undergo fresh embryo transfer (590 cases), Group B will undergo elective cryopreservation of all embryos followed by transfer of thawed embryos to a programmed endometrium (590 cases). All of the participants will receive recombinant follicule stimulating hormone (rFSH)/GnRH antagonist protocol for ovarian stimulation and standardized luteal phase support.
The target population will be infertile PCOS patients aged between 20 and 35 years, diagnosed by the Chinese PCOS Criteria(i.e. menstrual disorders PLUS either one of the remaining two criteria, hyperandrogenism or polycystic ovaries on ultrasound, with exclusion of secondary causes of hyperandrogenism and ovulation dysfunction). And subjects will be those who are undergoing their first IVF or intracytoplasmatic sperm injection (ICSI) cycle without other known factors interfere reproductive or metabolic functions.
The randomization will take place at the oocyte pick-up day by an on-line randomization system.
The pregnancy test results, pregnancy complications, congenital anomalies neonatal complications will be followed up by checking medical records and telephone calls.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230022
- The First affiliated Hospital of Anhui Medical University
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- The First Affiliated Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Guangdong, China, 510120
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
-
Guangxi
-
Nanning, Guangxi, China, 530003
- Guangxi Maternal and Child Health Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Renmin Hospital of Wuhan University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Jiangxi Maternal and Child Health Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Reproductive Medicine Center in Shenyang City
-
-
Shandong
-
Jinan, Shandong, China, 250001
- Reproductive medical hospital affiliated to Shandong University
-
Yantai, Shandong, China, 264000
- Yuhuangding Hospital in Yantai
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
-
Shanxi
-
Xi'an, Shanxi, China, 710003
- Shanxi Provincial Maternity and Children's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women diagnosed as PCOS according to Chinese PCOS diagnosis criteria;
- Women who have ≥1 years history of infertility;
- Women aged ≥20 and <35 years old;
- Women with body weight ≥40kg;
Women who have at least one of the following indications for IVF or ICSI:
- Ovulation dysfunction and failed to become pregnant from ovulation induction treatment;
- Tubal factors: unilateral or bilateral tubal obstruction, adhesion, unilateral or bilateral Salpingectomy or tubal ligation;
- Male factors: oligoasthenozoospermia, obstructive azoospermia;
- Women who are undergoing their first cycle of IVF or ICSI;
- Women who retrieved oocytes number > 3;
- Women who are capable of giving informed consent.
Exclusion Criteria:
- Women who underwent unilateral ovariectomy;
- Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicomis), adenomyosis, submucous myoma, intrauterine adhesion;
- Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
- Women who have experienced recurrent spontaneous abortion (including biochemical pregnancy abortion) more than 2 times;
- Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy;
- Women who has developed severe OHSS before oocyte pick-up day;
- Women with retrieved oocytes number ≤3;
- Women who are unable to comply with the study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fresh embryo transfer group
rFSH/GnRH antagonist will be administered for ovarian stimulation.
Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group.
Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not.
If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation.
Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
|
rFSH/GnRH antagonist will be administered for ovarian stimulation.
Oocyte pick-up will be performed when at least two follicles ≥18mm.
Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group.
Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not.
If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation.
Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
|
Experimental: frozen-thawed embryo transfer group
rFSH/GnRH antagonist will be administered for ovarian stimulation.
All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium.
Luteal phase support will last 2 weeks for all subjects in this group.
Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not.
If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation.
Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
|
rFSH/GnRH antagonist will be administered for ovarian stimulation.
Oocyte pick-up will be performed when at least two follicles ≥18mm.
All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium.
Luteal phase support will last 2 weeks for all subjects in this group.
Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not.
If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation.
Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
live birth rate
Time Frame: 10 months for group A, 12 months for group B
|
This will be based on the outcome of either the fresh embryo transfer after ovarian stimulation (Group A) or the outcome of the first frozen embryo transfer cycle (Group B) as will all other secondary outcomes.
|
10 months for group A, 12 months for group B
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ovarian hyperstimulation syndrome (OHSS) incidence
Time Frame: 2 months in maximum estimated
|
2 months in maximum estimated
|
|
clinical pregnancy rate
Time Frame: 35 days after embryo transfer
|
This will be based on the visualization of a intrauterine gestational sac by ultrasound.
|
35 days after embryo transfer
|
Pregnancy Loss rate
Time Frame: 28 weeks gestation in maximum
|
Loss of pregnancy will be defined by any positive pregnancy test that does not result in a live birth and will be tracked.
|
28 weeks gestation in maximum
|
ectopic pregnancy rate
Time Frame: 7~8 weeks gestation
|
7~8 weeks gestation
|
|
singleton live birth rate
Time Frame: 10 months for group A, 12 months for group B
|
10 months for group A, 12 months for group B
|
|
pregnancy complication rate
Time Frame: 10 months for group A, 12 months for group B
|
Complications of pregnancy including gestational hypertension, diabetes, preterm labor, disorders of placentation will be collected in all patients with ongoing clinical pregnancies.
|
10 months for group A, 12 months for group B
|
Congenital Anomalies rate
Time Frame: 10 months for group A, 12 months for group B
|
We will collect all recognized fetal and infant anomalies that occur within the trial.
|
10 months for group A, 12 months for group B
|
neonatal complication rate
Time Frame: within one month after labor
|
We will collect complications that occur in the neonate including admission to the neonatal intensive care unit (NICU), hospitalization, etc.
|
within one month after labor
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Zi-jiang Chen, MD, Repreductive medical hospital affiliated to Shandong University
Publications and helpful links
General Publications
- [1] Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12:673-83,2006. [2] Hayashi M, Nakai A, Satoh S, et al. Adverse obstetric and perinatal outcomes of singleton pregnancies may be related to maternal factors associated with infertility rather than the type of assisted reproductive technology procedure used. Fertil Steril 98:922-928,2012. [3] Chen XK, Wen SW, Bottomley J, et al. In vitro fertilization is associated with an increased risk for preeclampsia. Hypertens Pregnancy 28:1-12,2009. [4] Thomopoulos C, Tsioufis C, Michalopoulou H, et al. Assisted reproductive technology and pregnancy-related hypertensive complications: a systematic review. J Hum Hypertens 27:148-57,2013. [5] Haavaldsen C, Tanbo T, Eskild A. Placental weight in singleton pregnancies with and without assisted reproductive technology: a population study of 536,567 pregnancies. Hum Reprod 27:576-82,2012. [6] Maheshwari A, Pandey S, Shetty A, et al. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 98:368-77 e1-9,2012. [7] Kalra SK, Ratcliffe SJ, Coutifaris C, et al. Ovarian stimulation and low birth weight in newborns conceived through in vitro fertilization. Obstet Gynecol 118:863-871,2011.
- Zaat T, Zagers M, Mol F, Goddijn M, van Wely M, Mastenbroek S. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD011184. doi: 10.1002/14651858.CD011184.pub3.
- Wei D, Yu Y, Sun M, Shi Y, Sun Y, Deng X, Li J, Wang Z, Zhao S, Zhang H, Legro RS, Chen ZJ. The Effect of Supraphysiological Estradiol on Pregnancy Outcomes Differs Between Women With PCOS and Ovulatory Women. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2735-2742. doi: 10.1210/jc.2018-00613.
- Zhang B, Wei D, Legro RS, Shi Y, Li J, Zhang L, Hong Y, Sun G, Zhang T, Li W, Chen ZJ. Obstetric complications after frozen versus fresh embryo transfer in women with polycystic ovary syndrome: results from a randomized trial. Fertil Steril. 2018 Feb;109(2):324-329. doi: 10.1016/j.fertnstert.2017.10.020. Epub 2018 Jan 17.
- Wei D, Zhang B, Shi Y, Zhang L, Zhao S, Du Y, Xu L, Legro RS, Zhang H, Chen ZJ. Effect of Preconception Impaired Glucose Tolerance on Pregnancy Outcomes in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3822-3829. doi: 10.1210/jc.2017-01294.
- Wei D, Shi Y, Li J, Wang Z, Zhang L, Sun Y, Zhou H, Xu Y, Wu C, Liu L, Wu Q, Zhuang L, Du Y, Li W, Zhang H, Legro RS, Chen ZJ. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017 Feb;32(2):354-361. doi: 10.1093/humrep/dew325. Epub 2016 Dec 19.
- Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, Yang J, Liu J, Wei D, Weng N, Tian L, Hao C, Yang D, Zhou F, Shi J, Xu Y, Li J, Yan J, Qin Y, Zhao H, Zhang H, Legro RS. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2016 Aug 11;375(6):523-33. doi: 10.1056/NEJMoa1513873. Erratum In: N Engl J Med. 2016 Nov 17;375(20):2010.
- Shi Y, Wei D, Liang X, Sun Y, Liu J, Cao Y, Zhang B, Legro RS, Zhang H, Chen ZJ. Live birth after fresh embryo transfer vs elective embryo cryopreservation/frozen embryo transfer in women with polycystic ovary syndrome undergoing IVF (FreFro-PCOS): study protocol for a multicenter, prospective, randomized controlled clinical trial. Trials. 2014 May 2;15:154. doi: 10.1186/1745-6215-15-154.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SDUIVF001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
-
Odense University HospitalCompleted
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedPolycystic Ovary Syndrome (PCOS)United States
Clinical Trials on fresh embryo transfer
-
The University of Hong KongPeking University Third Hospital; Nanfang Hospital of Southern Medical University and other collaboratorsTerminated
-
Cairo UniversityRecruiting
-
Fertility Center of Las VegasWithdrawnInfertility | SubfertilityUnited States
-
University Hospital Virgen de las NievesJunta de AndalucíaCompletedPregnancy Rate | Single Embryo Transfer | Embryo Implantation, DelayedSpain
-
IgenomixCompletedEndometrial ReceptivitySpain, Belgium, Brazil, Bulgaria, Japan, Panama, Turkey
-
Fertility Center of Las VegasFerring PharmaceuticalsCompletedInfertilityUnited States
-
Fertility Center of Las VegasSchering-PloughCompletedInfertilityUnited States
-
Karolinska InstitutetCompletedPregnancy | Venous Thromboembolism | Frozen Embryo Transfer | Pulmonary Embolism | Assisted Reproductive Techniques | Fresh Embryo Transfer
-
Istituto Clinico HumanitasCompletedPregnancy Related | Ovarian Hyperstimulation Syndrome
-
Tanta UniversityRecruitingInfertility | IVF | Cryopreservation | ICSIEgypt